Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $20.40 Average Target Price from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have earned an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $20.40.

A number of research firms recently weighed in on ARTV. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Cantor Fitzgerald decreased their price target on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 25th. Wedbush restated an “outperform” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday, April 8th.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $1.90 on Friday. Artiva Biotherapeutics has a 12 month low of $1.78 and a 12 month high of $17.31. The company has a 50-day moving average price of $3.32 and a two-hundred day moving average price of $7.03.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several large investors have recently bought and sold shares of the business. Deutsche Bank AG bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at $216,000. BNP Paribas Financial Markets grew its stake in shares of Artiva Biotherapeutics by 262.1% during the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock worth $100,000 after purchasing an additional 7,151 shares during the period. Northern Trust Corp increased its holdings in Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after purchasing an additional 4,335 shares during the last quarter. Barclays PLC lifted its stake in Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock valued at $244,000 after buying an additional 4,545 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after buying an additional 3,361 shares during the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.